[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 490
Citations 0
Editor's Note
March 2016

The Financial Associations of Public Speakers at Meetings of Federal Health Advisory Committees

JAMA Intern Med. 2016;176(3):391. doi:10.1001/jamainternmed.2015.8092

Federal health advisory committees in the United States meet in public. Public speakers who travel to the Washington, DC, or Baltimore areas to attend meetings of the committees that advise the US Food and Drug Administration (FDA) or the Centers for Medicare & Medicaid Services (CMS) often have ties to companies with a financial stake in the outcome of the deliberations. In this issue of JAMA Internal Medicine, Abola and Prasad1 put numbers on a somewhat predictable finding. They analyze the characteristics of speakers at meetings of the FDA’s Oncologic Drugs Advisory Committee and find that a substantial proportion have financial associations with the company seeking marketing approval for a drug or medical device or an organization that receives financial support from the company.1 Most of the financial ties were disclosed, but not all.

First Page Preview View Large
First page PDF preview
First page PDF preview